Overview

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Status:
RECRUITING

Trial end date:
2030-03-14

Target enrollment:

Participant gender:

Summary

This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy

Phase:

PHASE3

Details

Lead Sponsor:

AstraZeneca

Treatments:

atezolizumab
Bevacizumab
tremelimumab